What is the role of granulocyte colony-stimulating factor (G-CSF) in the treatment of aplastic anemia?

Updated: Jan 29, 2021
  • Author: Sameer Bakhshi, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Adding granulocyte colony-stimulating factor (G-CSF) to ATG and cyclosporine does not provide a survival advantage, but the lack of a neutrophil response by day 30 in patients receiving G-CSF has been associated with significantly lower rate of response to immunosuppressive therapy, and  this early identification of probable nonresponders may stimulate an urgent transplant approach. [90] A study from the European Group of Blood and Marrow Transplantation found that adding G-CSF to ATG plus cyclosporine had no meaningful long-term effect. On median follow-up of 11.7 years, there was no significant difference in overall survival, event-free survival, or incidence of clonal disorders. [91]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!